• 1. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 2. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 3. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 4. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 5. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847

9BETA,11ALPHA,15S-TRIHYDROXY-PROSTA-5Z,13E-DIEN-1-OIC ACID, TRIS (HYDROXYMETHYL)AMINOMETHANE SALT: A Comprehensive Scientific Profile

The compound 9beta,11alpha,15S-trihydroxy-prosta-5Z,13E-dien-1-oic acid, tris (hydroxymethyl)aminomethane salt (CAS 89847-02-9) represents an important derivative in the prostaglandin family. This chemically modified prostaglandin analog has gained significant attention in pharmaceutical research due to its unique structural characteristics and potential therapeutic applications. The tris(hydroxymethyl)aminomethane salt formulation enhances the compound's stability and solubility, making it particularly valuable for biomedical applications.

Structurally, this compound features a prostanoic acid backbone with hydroxyl groups at the 9beta, 11alpha, and 15S positions, along with 5Z,13E-diene configuration. The tromethamine salt form (derived from tris(hydroxymethyl)aminomethane) significantly improves the compound's physicochemical properties. Researchers have shown particular interest in this derivative because of its potential to modulate various physiological processes while maintaining improved stability compared to native prostaglandins.

Recent scientific literature highlights several emerging applications for 9beta,11alpha,15S-trihydroxy-prosta-5Z,13E-dien-1-oic acid tromethamine salt. In ophthalmology, studies suggest potential benefits in ocular surface disorders due to its ability to regulate inflammation and promote tissue healing. The compound's unique hydroxylation pattern appears to influence receptor binding specificity, potentially offering advantages over conventional prostaglandin analogs currently used in clinical practice.

The pharmaceutical industry has shown growing interest in prostaglandin derivatives like this compound, particularly in the development of novel topical formulations. Current research focuses on optimizing delivery systems to enhance bioavailability while minimizing systemic exposure. The tris(hydroxymethyl)aminomethane salt form has demonstrated improved transdermal penetration in preclinical models, suggesting potential for dermatological applications.

From a chemical perspective, the 9beta,11alpha,15S-trihydroxy configuration contributes to the molecule's stereochemical complexity. Analytical characterization typically employs advanced techniques such as chiral HPLC and mass spectrometry to ensure purity and confirm the 5Z,13E-diene configuration. The salt formation with tromethamine has been shown to enhance the compound's crystalline properties, facilitating purification and formulation processes.

In biochemical studies, this prostaglandin derivative has demonstrated interesting receptor binding profiles. While it maintains affinity for classical prostaglandin receptors, the specific hydroxylation pattern appears to modulate downstream signaling pathways differently than native prostaglandins. These subtle differences may account for the compound's unique pharmacological effects observed in various experimental models.

The synthesis of 9beta,11alpha,15S-trihydroxy-prosta-5Z,13E-dien-1-oic acid tromethamine salt typically involves multi-step organic transformations starting from prostaglandin precursors. Key steps include stereoselective hydroxylation and subsequent salt formation with tris(hydroxymethyl)aminomethane. Process optimization has focused on improving yields while maintaining the critical 5Z,13E-diene configuration throughout the synthetic sequence.

Stability studies indicate that the tromethamine salt form provides superior protection against degradation compared to the free acid form. This enhanced stability is particularly important for pharmaceutical applications where shelf life is a critical consideration. The compound demonstrates optimal stability in slightly alkaline conditions, consistent with the buffering properties of tris(hydroxymethyl)aminomethane.

Current market trends show increasing demand for specialized prostaglandin analogs in both research and potential therapeutic applications. The unique properties of 9beta,11alpha,15S-trihydroxy-prosta-5Z,13E-dien-1-oic acid tromethamine salt position it as an interesting candidate for further development. Pharmaceutical companies are particularly interested in its potential for ocular and dermatological indications where modified prostaglandins have shown clinical success.

From a regulatory perspective, the compound's status as a prostaglandin derivative places it within established frameworks for similar molecules. While not currently approved for therapeutic use, its development follows pathways well-characterized for other prostanoic acid derivatives. The tris(hydroxymethyl)aminomethane salt form is generally recognized as pharmaceutically acceptable, simplifying formulation development.

In research applications, CAS 89847-02-9 has become a valuable tool for studying prostaglandin receptor pharmacology. Its unique hydroxylation pattern provides insights into structure-activity relationships within this important class of lipid mediators. Scientists frequently employ this compound to probe subtle differences in receptor activation profiles compared to native prostaglandins.

The future development of 9beta,11alpha,15S-trihydroxy-prosta-5Z,13E-dien-1-oic acid tromethamine salt will likely focus on expanding its potential therapeutic applications. Ongoing research explores its effects on tissue remodeling, angiogenesis, and inflammation modulation. The compound's 5Z,13E-diene configuration and specific hydroxyl group positioning continue to make it a molecule of significant scientific interest.

• 35700-23-3(Carboprost)
• 38562-01-5(Dinoprost tromethamine salt)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)